These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Tumor vaccine strategies that employ dendritic cells and tumor lysates: experimental and clinical studies. Mulé JJ Immunol Invest; 2000 May; 29(2):127-9. PubMed ID: 10854180 [No Abstract] [Full Text] [Related]
6. Present and future of cancer vaccines. Hockertz S Toxicology; 2005 Oct; 214(1-2):151-61. PubMed ID: 16259078 [No Abstract] [Full Text] [Related]
7. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Ribas A; Timmerman JM; Butterfield LH; Economou JS Trends Immunol; 2003 Feb; 24(2):58-61. PubMed ID: 12547500 [TBL] [Abstract][Full Text] [Related]
8. Current status and future applications of cellular therapies for cancer. Copier J; Bodman-Smith M; Dalgleish A Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192 [TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines: finding the best way to train the immune system. Goldman B J Natl Cancer Inst; 2002 Oct; 94(20):1523-6. PubMed ID: 12381703 [No Abstract] [Full Text] [Related]
13. Current developments of immunotherapy in the clinic. Antonia S; Mulé JJ; Weber JS Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403 [TBL] [Abstract][Full Text] [Related]
14. Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I. Quatan N; Spicer J; Plunkett T; Pandha H Clin Oncol (R Coll Radiol); 2004 Aug; 16(5):356-65. PubMed ID: 15341440 [No Abstract] [Full Text] [Related]